论文信息 - Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia - 字舞流文

Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia

S. Tummala | Sheeba K. Thomas | E. Manasanch | D. Cachia | Walla A. Alfaraj

[1] S. Treon,et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. , 2014, Blood.

[2] M. Dimopoulos,et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). , 2013, Blood.

[3] P. Richardson,et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia , 2010, American journal of hematology.

[4] D. Esseltine,et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5] S. Treon. How I treat Waldenström macroglobulinemia. , 2009, Blood.

[6] J. Crowley,et al. International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.

[7] R. Nemni,et al. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab. , 2006, Haematologica.

[8] V. Noronha,et al. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.